Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998, for Celsion Corporation (formerly Cheung Laboratories, Inc.). The company is a biotechnology firm developing minimally invasive thermotherapy devices for cancer and benign prostatic hyperplasia (BPH). The company recently changed its name to Celsion Corporation effective May 1, 1998, and is pivoting its strategy to focus on Adaptive Phase Array (APA) technology licensed from MIT and balloon catheter technology, while ceasing active sales of current equipment.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 1998 | Six Months Ended Mar 31, 1997 |
|---|---|---|
| Total Revenue | $110,260 | $113,293 |
| Gross Profit | $64,760 | $69,182 |
| Net Loss | ($1,914,181) | ($1,040,948) |
| Loss Per Share (Basic) | ($0.06) | ($0.04) |
| Cash and Equivalents (End of Period) | $112,883 | $6,756 |
| Net Cash Used in Operating Activities | ($1,935,218) | ($616,886) |
| Total Liabilities | $1,855,710 | $3,283,855 |
| Stockholders' Deficit | ($1,109,145) | ($2,460,646) |
Debt and Liquidity: The company holds no long-term debt. Current liabilities include approximately $142,542 in notes payable (other) and $32,148 in notes payable to related parties. The company has an accumulated deficit of $17,177,704.
Material Changes vs. Prior Period
- Revenue: Revenue remained relatively flat, decreasing slightly by 2.7% year-over-year ($110,260 vs. $113,293) as the company ceased active sales of legacy equipment to focus on R&D.
- Operating Expenses: Total operating expenses increased significantly to $1,942,176 from $1,016,112. This was driven by a 1,325% increase in Research and Development (R&D) expenses ($601,107 vs. $42,101) and a 37.7% increase in Selling, General, and Administrative (SG&A) expenses ($1,341,069 vs. $974,011).
- Net Loss: The net loss widened by 83.9% to $1.91 million, reflecting the heavy investment in new technology development.
- Capital Structure: The company raised $1,853,876 in proceeds from stock issuances during the six-month period. Additionally, $1,411,808 of debt and accrued interest was converted into common stock.
- Liquidity: Cash balances decreased by $154,470 during the period, ending at $112,883, despite the equity raise, due to high operating cash burn.
Outlook, Risks, and Management Commentary
Outlook and Guidance: Management states that existing capital resources are inadequate to fund operations for the next twelve months. The company is dependent on raising additional capital to continue product development and FDA approval processes. Future revenue is not expected until new technologies are developed and approved.
Risks and Contingencies:
- Liquidity Risk: The company explicitly states it must raise additional cash to continue operations and has no firm commitments for such funding. Failure to secure capital could force the company to delay or eliminate operations.
- Legal Proceedings: The company is a defendant in a lawsuit filed by Eastwell Management Services, Ltd., seeking damages of $125,000 (with a motion to increase to $250,000 plus punitive damages). The company denies liability.
- Product Liability: The company does not maintain a product liability insurance policy, which could materially adversely affect financial condition if a claim is asserted.
- Regulatory Risk: Commercialization depends on FDA approval, which is uncertain and time-consuming.
Investor Verification Checklist
- Verify the status of the Eastwell Management Services lawsuit and potential liability exposure.
- Confirm the timeline and progress of FDA approvals for the APA and balloon catheter technologies.
- Assess the company's ability to secure the necessary equity or debt financing to survive the next 12 months given the current cash burn rate.
- Review the details of the recent stock issuances and the dilution impact on existing shareholders.
- Investigate the lack of product liability insurance and the potential financial impact of a claim.